HDP-102 / Heidelberg Pharma, Huadong Medicine - LARVOL DELTA

HDP-102 - a CD37-targeting Amanitin-based-ADC for the treatment of NHL - non-clinical data package (AACR 2024) - "CD37 is an ideal target for ADCs due to its high prevalence in B-cell malignancies and limited expression on healthy cells. We have demonstrated that the anti-CD37 ATAC HDP-102 is a promising drug candidate for the treatment of NHL. HDP-102 showed excellent anti-tumor efficacy in CDX models even after single doses."

ADC • Clinical data • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

PR: Heidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma (Heidelberg Pharma Press Release) - "Heidelberg Pharma AG...today announced that the first patient has been dosed in a Phase I clinical study evaluating HDP-102 for the treatment of non-Hodgkin lymphoma (NHL)....The first patient has been dosed with HDP-102 in a study center in the Republic of Moldova....Heidelberg Pharma presented preclinical data for HDP-102 at the American Association for Cancer Research (AACR) 2024 Annual Meeting. The data demonstrated strong anti-tumor efficacy and favorable tolerability following a single administration."

Preclinical • Trial status • Non-Hodgkin’s Lymphoma

Heidelberg Pharma AG Launches Rights Issue of up to EUR 80 Million (PharmiWeb) - "Heidelberg Pharma AG intends to use the proceeds from the funding mainly to conduct the ongoing Phase I trial with HDP-101, as well as to advance the further development of follow-on projects, HDP-102 and HDP-103, and the proprietary ATAC® technology."

Commercial • Oncology